Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 13/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2799485 | 0.86 | CAPN1 (0.62) | CAPN1CTSS | |
| SCHEMBL2800282 | 0.81 | PYGL (0.47) | CAPN1PYGLCCR1 | |
| SCHEMBL2801618 | 0.77 | CAPN1 (0.75) | CAPN1PYGLCTSSCTSBCCR1 | |
| SCHEMBL2799940 | 0.74 | KDM4E (0.56) | NQO2 | |
| SCHEMBL541246 | 0.74 | CAPN1 (0.75) | CAPN1CTSS | |
| SCHEMBL2803091 | 0.74 | ALDH1A1 (0.58) | CAPN1PYGLCCR1 | |
| SCHEMBL2800741 | 0.74 | CAPN1 (0.47) | CAPN1PYGLCCR1 | |
| SCHEMBL7322290 | 0.73 | CHRNB2 (0.52) | CAPN1PYGLCTSB | |
| SCHEMBL2802814 | 0.72 | CAPN1 (0.67) | CAPN1PYGL | |
| SCHEMBL3711942 | 0.72 | CAPN1 (0.87) | CAPN1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567325-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-02-14 | — | — | US | disclosed |
| US-20150045394-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-02-12 | — | — | US | disclosed |
| US-8906941-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20100216844-A1 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045394-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAMK4, CAMK2A, CAMK2B | CAPN1 4/4885PYGL 417/4885CTSS 40/4885 |
| US-20100216844-A1 | Carboxamide compounds and their use as calpain inhibitors | CAMK4, CAMK2A, CAMK2B | CAPN1 4/4885PYGL 436/4885CTSS 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.